港交所医疗IPO（首次公开募股）阵营再添一员川军。近日，由知名川商耿福能创立的好医生云医疗正 式递表港交所主板。从一家小小药材收购店起家，到如今构建起覆盖医药工业、商业与基层医疗的庞大 网络，耿氏家族的商业版图再度扩张。 招股书揭开了好医生云医疗浓厚的家族底色。从股权结构看，耿福能与其弟耿福昌持有约三成股份；女 儿GENG Jie通过境外实体持股超21%，并出任董事会主席，执掌战略方向；儿子耿越飞亦持有部分股权 并担任非执行董事。GENG Jie的配偶薛源则以执行董事兼首席技术官的身份深度参与运营。 通过一致行动协议，耿氏家族牢牢掌控着企业近66%的表决权。这种"父辈创业、子女接班、姻亲赋 能"的模式，构成中国家族企业的典型样本。 此外，招股书披露的关联交易脉络，也映射出耿氏家族纵横交错的商业布局。其家族控制或参股的企业 在好医生云医疗的客户及供应商版图中扮演重要角色。 耿氏家族企业冲刺港交所上市 近期，奔赴港交所上市的医药企业"前赴后继"，基层医疗服务商——好医生云医疗也加入其中。 据港交所披露，好医生云医疗已正式递交上市申请，海通国际与中信证券担任联席保荐人。招股书显 示，好医生云医疗是领先的综合性基层医 ...

Core Viewpoint - Good Doctor Cloud Medical has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International and CITIC Securities as joint sponsors [1] Company Summary - Good Doctor Cloud Medical is a comprehensive grassroots medical empowerment platform, ranking second in China's grassroots medical empowerment service industry based on projected revenue for 2024 [1] - As of December 31, 2024, the company ranks second in the number of grassroots medical terminal customers in China [1] - It is the only comprehensive empowerment platform in China's grassroots medical industry that utilizes digital intelligence and AI-assisted empowerment [1] - As of June 30, 2025, the company has directly served over 660,600 grassroots medical terminal customers, including grassroots medical institutions and pharmacies [1] - The number of registered grassroots medical terminal customers has grown at a compound annual growth rate (CAGR) of 29.0% from December 31, 2022, to December 31, 2024 [1] - By June 30, 2025, the customer coverage has expanded to over 99% of county-level administrative regions in China [1] Industry Summary - The market size of China's grassroots medical industry is substantial, with an expected compound annual growth rate (CAGR) of 9.2% from 2024 to 2030 [1]

据港交所9月30日披露，四川好医生云医疗科技集团股份有限公司(简称：好医生云医疗)向港交所主板提交上市申请书，海通国际及中信证券为联席保荐 人。 | 編纂]項下的[編纂]總數 ： [編纂]股H股(視乎[編纂]行使與否而定） | | --- | | [編纂]數目 .. [編纂]股H股(可予[編纂]) | | [編纂]數目 :「編纂】股H股(視乎[編纂]行使與否而定 | | 及可予[編纂]) | | 最高[編纂] : 每股H股[編纂]港元,另加1.0%經 | | 紀佣金、0.0027%證監會交易徵 | | 費、0.00015%會財局交易徵費及 | | 0.00565%香港聯交所交易費(須於申 | | 請時以港元繳足,多繳股款可予退還) | | 咱偵 : 每股H股人民幣0.1元 | 据招股书披露，好医生云医疗是中国领先的综合性基层医疗赋能平台，致力于让优质医疗资源下沉至基层市场，让基层老百姓在家门口享受三级医院水平的 医疗服务和产品。 根据灼识咨询的资料，以2024年收入计，公司在中国基层医疗赋能服务行业排名第二。截至2024年12月31日，以基层医疗终端客户(包括(i)涵盖村卫生站、 门诊部及诊所的基层医疗机构， ...

Core Viewpoint - Sichuan Good Doctor Cloud Medical Technology Group Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Haitong International and CITIC Securities as joint sponsors [1] Company Overview - Good Doctor Cloud Medical is a leading comprehensive grassroots medical empowerment platform in China, aiming to provide high-quality medical resources to grassroots markets, allowing local residents to access tertiary hospital-level medical services and products [5] - The company ranks second in China's grassroots medical empowerment service industry based on revenue as of 2024 [7] Market Position - As of June 30, 2025, Good Doctor Cloud Medical has directly served over 660,600 grassroots medical terminal customers, including over 389,300 grassroots medical institutions and 271,300 grassroots pharmacies [8] - The company is the only comprehensive empowerment platform in China's grassroots medical industry that utilizes digital intelligence and AI assistance, offering integrated solutions covering testing, diagnosis, medication, and treatment [7][8] Customer Growth - The number of registered grassroots medical terminal customers has grown at a compound annual growth rate (CAGR) of 29.0% from December 31, 2022, to December 31, 2024 [9] - The average monthly paying customer count increased from over 83,800 in 2022 to over 121,900 in 2024, reflecting a CAGR of 20.6% [9] Industry Insights - The grassroots medical industry in China is substantial, consisting of approximately 1.636 million grassroots medical terminals, including about 1.04 million grassroots medical institutions and 291,000 single pharmacies [9] - The market size of China's grassroots medical industry is projected to reach RMB 544.5 billion in 2024, with an expected CAGR of 9.2% from 2024 to 2030, reaching RMB 922 billion by the end of 2030 [9] Financial Performance - For the fiscal years ending June 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 3.065 billion, RMB 3.264 billion, and RMB 1.891 billion, respectively [10] - The profits for the same periods were RMB 62.48 million, RMB 37.81 million, and RMB 35.77 million, respectively [10]